FDA clears Carl Zeiss' OCT (Optical Coherence Tomographer) screener for retinal diseases:
This article was originally published in Clinica
Executive Summary
Carl Zeiss Ophthalmic Systems has received US FDA clearance to market its Optical Coherence Tomographer (OCT) model 3000 for screening for retinal diseases. The device provides real-time cross-sectional images of retinal tissue that have axial resolution of ten microns or less. It enables physicians to avoid invasive procedures and see below the surface of the retina, allowing them to directly measure internal retinal structures that can help in the diagnosis of diseases, such as glaucoma. A typical examination using the device takes less than 10 minutes, says the Dublin, California firm.